Engineered Myeloma Models Reveal Spatial Tumor–Stroma Dependencies

• Engineered myeloma models (GEMM/CDX) with spatial transcriptomics to resolve tumor microenvironment architecture
• Targeted NSD2 degradation disrupts supportive niches and reprograms myeloma–stroma signaling in situ
• Model-guided framework to rank combinations and de-risk translation for next-gen multiple myeloma therapies

Speakers:

Bo Hu

Scientist

Bristol Myers Squibb